HomeAI · summaries
Storia in 13 fonti
Trial of next-gen weight-loss drug retatrutide shows users lose almost a third of their body weight
While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As…
- ·
qz.com
Eli Lilly retatrutide Phase 3 obesity trial results 2026
The triple-hormone injection outpaced existing weight loss drugs and approached bariatric surgery outcomes in an 80-week study
